OccuLogix, Inc.
Medical Devices & Tech  Advamed Member
2600 Skymark Avenue, Building 9, Suite 201
Mississauga, Ontario L4W 5B2 Canada
phone: 866-622-8564
fax: 905-602-7623
Symbol OCCX
Exchange Nasdaq
Founded 0
Employees
www.occulogix.com
Research Sector Medical Devices & Tech
Summary Description
Treatments for eye diseases including age-related macular degeneration.
Management
Doug Adams, President and Founder, SOLX Division; Nozhat Choudry, PhD, Vice President, Clinical Research; John Cornish, Vice President, Operations; William (Bill) G. Dumencu, CA, Interim Chief Financial Officer and Treasurer; David Eldridge, OD, FAAO, Vice President, Science and Technology; Julie A. Fotheringham, Vice President, Marketing; Stephen J. Kilmer, Vice President, Investor and Public Affairs; Steve Parks, Vice President, Sales; Thomas P. Reeves, President and Chief Operating Officer; Elias Vamvakas, Chairman and CEO; Steve Westing, Dr.Med.Sc., Vice President, Medical and Scientific Development
Ownership
Financials


* numbers in thousands

 
Keywords
ophthalmology, eye, vision, eye disease, macular degeneration, amd, advamed

Comment | Printable Version | Nov. 01, 2008
If you work for OccuLogix, Inc. and want to update this profile, click here

Description
OccuLogix operates as an ophthalmic therapeutic company offering solutions for eye diseases, including age-related macular degeneration (AMD).
Products / Services
The Company's primary product is the RHEO System which consists of the OctoNova Pump and a disposable treatment set that improve microcirculation in the eye by filtering high molecular weight proteins and other macromolecules from the patient's plasma.
Technology / Differentiation
The RHEO(tm)System uses a double filtration apheresis process, whereby a pair of single-use blood and plasma filters sequentially separate and partially remove the targeted plasma components. The system removes macromolecules greater than a specified size from the plasma.
Market / Customers
Approximately 15 million people in the United States suffer from AMD, many of them aged 65 and older. With a growing aging population, AMD procedures are expected to increase.
Competitors / Substitutes / Alternatives
Acuity Medical, Inc.
Strategy
Occulogix mission is to establish RHEO(tm) Therapy as the leading treatment for Dry AMD in North America. The key strategies include creating a plan to develop market awareness of RHEO(tm) Therapy by educating eye care professionals and patients, establish third-party reimbursement for RHEO(tm) Therapy, secure relationships with key multi-facility health care service providers and ensure sufficient manufacturing capacity and inventory to support their commercialization plan.


2008-11-23-628